1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win

Positive Phase III For Ionis-Partnered Antisense Candidate

 
• By Kevin Grogan

AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
• Source: Archive

AstraZeneca PLC and Ionis Pharmaceuticals, Inc. are close to entering the highly competitive transthyretin amyloidosis (ATTR) market after posting promising late-stage data on the antisense therapy eplontersen.

The UK major, which paid $200m upfront at the end of last year to get hold of eplontersen, has presented high-level results from a 35-week interim analysis of the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.